The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
AM23-SN-29-O: The Approach to Bleeding in Patients Receiving Targeted Factor XI Therapy (Enduring)
Credits
1 General Continuing Education (GEN) | 1 Florida Lab Personnel (FLP) | 1 California Nurse (CN) | 1 California Lab Personnel (CLP)
$3000
Standard Price
Members save $5
The ideal goal of anticoagulant therapy is to attenuate thrombosis without compromising hemostasis. Although newer oral anticoagulants such as apixaban, rivaroxaban, and edoxaban are associated with less intracranial hemorrhage than vitamin K antagonists, bleeding remains their major side effect. Because of the decreased bleeding risk associated with targeting Factor XI, there has been a tremendous interest in developing agents to inhibit Factor XI activity or to attenuate Factor XI levels. This session will review the role of Factor XI in the development of thrombosis and review current approaches in inhibiting or decreasing Factor XI activity. Results from animal models and recent clinical trials of FXIa inhibition will be presented. As a potentially new anticoagulant, approaches to the diagnosis and management when associated with bleeding will be discussed. These approaches will be discussed in the context of bleeding patients with congenital and acquired Factor XI deficiency.
Learning Objectives
Describe the role of Factor XI in coagulation and thrombosis
Understand the various mechanisms of action of potential agents that inhibit Factor XI activity and expression
3. Describe results from recent clinical studies targeting Factor XI as an anti-thrombotic agent
Develop approaches for the management of bleeding in patients who are undergoing treatments that target Factor XI activity or expression
All relevant financial relationships have been mitigated.
By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.
Credits Available
Purchasing this session will automatically provide ownership of all the individually purchasable attached CE products, regardless of their stated individual purchase restrictions.
AM23-SN-29-O: The Approach to Bleeding in Patients Receiving Targeted Factor XI Therapy (Enduring) Evaluation
This session will focus on the role of anti-fibrinolytics and other hemostatic agents/adjuncts (such as prothrombin concentrates, rFVIIa, fibrinogen concentrates/cryoprecipitate) in controlling bleeding and lowering transfusion needs in pediatric trauma situations…
Race is a sociopolitical and not biological construct. As such, the use of race-based algorithms and disease associations has caused demonstrable harm such as delayed kidney transplant referral and missed diagnoses. The field of transfusion medicine is not immune…
In today’s rapidly evolving healthcare environment, understanding the latest policy developments is crucial for strategic planning and operational success. This session will explore the significant implications of the recent Supreme Court decision – Loper Bright Enterprises v…